Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program

Published:2015-09-09 Issue:2 Volume:293 Page:271-281
ISSN:0932-0067
Container-title:Archives of Gynecology and Obstetrics
language:en
Short-container-title:Arch Gynecol Obstet

Author:

Schramm Amelie,Friedl Thomas W. P.,Schochter Fabienne,Scholz Christoph,de Gregorio Nikolaus,Huober Jens,Rack Brigitte,Trapp Elisabeth,Alunni-Fabbroni Marianna,Müller Volkmar,Schneeweiss Andreas,Pantel Klaus,Meier-Stiegen Franziska,Hartkopf Andreas,Taran Florin-Andrei,Wallwiener Diethelm,Janni Wolfgang,Fehm Tanja

Funder

Roche

Novartis (CH)

Janssen Research and Development (US)

GlaxoSmithKline (GB)

Pierre Fabre

Teva

Amgen

Novartis

Eisai (JP)

Publisher

Springer Science and Business Media LLC

Subject

Obstetrics and Gynecology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00404-015-3879-7.pdf

Reference37 articles.

1. Fehm T, Müller V, Aktas B et al (2010) HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat 124:403–412. doi: 10.1007/s10549-010-1163-x

2. Bidard F-C, Peeters DJ, Fehm T et al (2014) Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 15:406–414. doi: 10.1016/S1470-2045(14)70069-5

3. Budd GT, Cristofanilli M, Ellis MJ et al (2006) Circulating tumor cells versus imaging–predicting overall survival in metastatic breast cancer. Clin Cancer Res 12:6403–6409. doi: 10.1158/1078-0432.CCR-05-1769

4. Cristofanilli M, Hayes DF, Budd GT et al (2005) Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23:1420–1430. doi: 10.1200/JCO.2005.08.140

5. Hayes DF, Cristofanilli M, Budd GT et al (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12:4218–4224. doi: 10.1158/1078-0432.CCR-05-2821

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the Immunological Profile in Breast Cancer: Recent Advances in Diagnosis and Prognosis through Circulating Tumor Cells;International Journal of Molecular Sciences;2024-04-29

2. New treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023;Current Opinion in Obstetrics & Gynecology;2022-10-07

3. HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment;Frontiers in Bioengineering and Biotechnology;2022-09-28

4. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program;ESMO Open;2021-12

5. Liquid Biopsy in Metastatic Breast Cancer: Current Role of Circulating Tumor Cells and Circulating Tumor DNA;Oncology Research and Treatment;2021-10-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3